QUALITY OF LIFE IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS IN THE CONDITIONS OF TREATMENT WITH CHIMERIC MONOCLONAL ANTIBODIES TO TNF α
The article presents results of study of inhibitor TNF α — infliximab — on quality of life in patients with juvenile arthritis, refractory to standard immunosuppressive treatment. In 1.5 months after the beginning of treatment, the quality of life increased in 98% of patients; and in one year, the r...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2009-05-01
|
| Series: | Вопросы современной педиатрии |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/1113 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The article presents results of study of inhibitor TNF α — infliximab — on quality of life in patients with juvenile arthritis, refractory to standard immunosuppressive treatment. In 1.5 months after the beginning of treatment, the quality of life increased in 98% of patients; and in one year, the rates of physical functioning were similar to it in healthy children the same age.Key words: children, juvenile arthritis, quality of life, infliximab.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(3):18-26) |
|---|---|
| ISSN: | 1682-5527 1682-5535 |